Targeted Protein Degradation: A Potential Tool for Discovering Druggable Targets
Drug discovery is the first step in therapeutic breakthroughs. Unfortunately, this cannot occur without target discovery - the identification and validation of druggable targets. Whether it be proteins or small molecules, discovering a ‘druggable’ biological target can be a challenge...
4 years agoTargeted Protein Degradation: A Potential Tool for Discovering Druggable Targets
Drug discovery is the first step in therapeutic breakthroughs. Unfortunately, this cannot occur without target discovery - the identification and validation of druggable targets. Whether it be proteins or small molecules, discovering a ‘druggable’ biological target can be a challenge...
4 years ago
Biobanks and EHR Data in Drug Design and Development
Over the last five years, drug design and development has evolved substantially with technological innovations. Electronic health records (EHRs) have played an important role in utilising health data on a digital platform in both preclinical and clinical studies. Biobanks have...
4 years agoBiobanks and EHR Data in Drug Design and Development
Over the last five years, drug design and development has evolved substantially with technological innovations. Electronic health records (EHRs) have played an important role in utilising health data on a digital platform in both preclinical and clinical studies. Biobanks have...
4 years ago
How Has The Covid-19 Pandemic Impacted Oncology and Clinical Operations?
As a part of Proventa’s Clinical Operations and Oncology Meeting May 2021, we organised a number of interesting keynote sessions pondering the latest innovations, challenges and strategies for the future. The morning keynote, hosted by Tanya Russel Kirkpatrick, VP Clinical...
4 years agoHow Has The Covid-19 Pandemic Impacted Oncology and Clinical Operations?
As a part of Proventa’s Clinical Operations and Oncology Meeting May 2021, we organised a number of interesting keynote sessions pondering the latest innovations, challenges and strategies for the future. The morning keynote, hosted by Tanya Russel Kirkpatrick, VP Clinical...
4 years ago
AstraZeneca/Alexion Purchase Held Up by CMA Amid Concerns
In December 2020, pharma giant AstraZeneca (AZ) announced its intention to acquire biopharmaceutical company Alexion. The merger would give AZ an increased portfolio in rare disease and immunology. While the US Federal Trade Commission (FTC) has approved the merger, several...
4 years agoAstraZeneca/Alexion Purchase Held Up by CMA Amid Concerns
In December 2020, pharma giant AstraZeneca (AZ) announced its intention to acquire biopharmaceutical company Alexion. The merger would give AZ an increased portfolio in rare disease and immunology. While the US Federal Trade Commission (FTC) has approved the merger, several...
4 years ago
The Great Debate: The Utilisation of True AI in All Aspects of Drug Discovery
As a part of Proventa’s Medicinal Chemistry and Biology Strategy Meeting May 2021, we organised a number of interesting keynote sessions pondering the latest innovations, challenges and strategies for the future. The morning keynote, hosted by Gilead’s Executive Director for...
4 years agoThe Great Debate: The Utilisation of True AI in All Aspects of Drug Discovery
As a part of Proventa’s Medicinal Chemistry and Biology Strategy Meeting May 2021, we organised a number of interesting keynote sessions pondering the latest innovations, challenges and strategies for the future. The morning keynote, hosted by Gilead’s Executive Director for...
4 years ago
Biomarker Discovery and Validation: Current Challenges in Oncology
Biomarkers have shown significant potential across oncology clinical studies, especially in precision medicine for immunotherapy. Therefore, it is important that biomarker discovery and validation is optimised to produce the most effective drugs for patient populations. False positives and experimental bias...
4 years agoBiomarker Discovery and Validation: Current Challenges in Oncology
Biomarkers have shown significant potential across oncology clinical studies, especially in precision medicine for immunotherapy. Therefore, it is important that biomarker discovery and validation is optimised to produce the most effective drugs for patient populations. False positives and experimental bias...
4 years agoInterested?
Reserve your space
